Oct 7 First Friday Bioscience – Getting to the Founding Vision: the journey to identify a strategic application…

Full Title: : Getting to the Founding Vision: the journey to identify a strategic application for a platform technology start-up that maximizes value and attracts financing.

Speaker: Bernadette C. Fendrock (Bonnie), Co-founder and CEO of Cyta Therapeutics Inc.

Host:

Walkins are always welcome after the close of online registration – there is a $5 surcharge for walkings. Save money – register in advance!

Description

Great technology is not enough to lead to a successful development. Technologies need to be translated into a solution that can solve the most intractable problems. What I call the “founding vision.” The next step is to build a plan with the most capable people to guide the development that identifies the resources and the time necessary to realize the vision. The most important questions are, can this vision create enough value to compensate everyone along the way, and can it be demonstrated. If not, reimagine the founding vision and build a new plan. Rinse and repeat, until you are ready to enter the scrum of the capital markets.

Location

Office of McLane Middleton Professional Assoc.
300 TradeCenter128, 7th Floor
Woburn MA USA

Date and Time

Begins: 10/07/2016 12:30 PM
Ends: 10/07/2016 02:00 PM

Speaker:

Bernadette C. Fendrock (Bonnie), Co-founder and CEO of Cyta Therapeutics Inc.

Bernadette C. Fendrock (Bonnie) is a life sciences executive and entrepreneur who has track record of building new businesses including start-ups and units within established organizations, fund raising, strategy and business development. Prior to Cyta Therapeutics, Ms Fendrock co-founded Hepregen, which was acquired by Ascendence Biotechnology, Inc.. Before Hepregen, Ms. Fendrock was Vice President at Genzyme Corporation working in Corporate Development, where she was responsible for the commercial planning and market launch strategies, and held management positions at Somatix, Inc. and Genetics Institute. . In 2012, Ms. Fendrock was honored along with other innovation leaders as one of the Mass High Tech ‘Women to Watch’.

Ms. Fendrock is a Director, Executive Women Series (EWS), for the Boston Chapter of the Healthcare Businesswomen’s Association (HBA) and has been an active volunteer mentor to entrepreneurs through several programs including The Deshpande Center at MIT, MassConnect at MassBio and MassChallenge.

Ms. Fendrock holds a B.A. degree with a major in Molecular Biology from Wellesley College, a S.M. degree from MIT in Interdisciplinary Science, and an M.B.A. from The Wharton School of the University of Pennsylvania.

Company:

https://images.massbio.org/Cyta-Therapeutics.jpg?mw210-mh210
Cyta Therapeutics (Cyta) is a next generation nanomedicines company based on novel chemistry developed in the laboratory of Professor Thayumanavan at UMass, Amherst, Cyta is commercializing a class of novel polymer-based nanogels, called IntelliGels, to address a spectrum of liver diseases which lack effective treatments and which will benefit from liver regeneration and cyto-protection (to reduce inflammation). Cyta has an exclusive option to license seven patent applications from UMass, Amherst and has filed its own IP.

Networking/Lunch

Registration, networking and lunch start at 12:30; Program
begins at 1 p.m.

See Who Has Registered:

To see who has registered for this event,
click here….

OnLine Registration

Online registration closes at 5 p.m. the day before this event. While walk-ins are never turned away, advance registration helps the team and is greatly appreciated.

Please note: The charge for All at the door registrations is $15.